Viral & Host Factors Associated With Hepatitis B Virus-Related Hepatocellular Carcinoma

This study is currently recruiting participants.

Verified by Stanford University, September 2008

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00767936

Purpose

Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection. The purpose of the study is to sequence the HBV genome in patients with chronic HBV infection, and in patients with liver cancer resulting from chronic HBV infection. The goal is to identify mutations in the HBV genome that predisposes these high risk individuals to the development of liver cancer.

Condition
Hepatitis B Liver Cancer Hepatitis C

MedlinePlus related topics: Cancer Hepatitis Hepatitis B Hepatitis C Liver Cancer

Drug Information available for: Hepatitis B Vaccines

U.S. FDA Resources

Study Type:	Observational
Study Design:	Retrospective
Official Title:	Viral and Host Factors Associated With Development of Hepatitis B Virus-Related Hepatocellular Carcinoma

Further study details as provided by Stanford University:

Estimated Enrollment:	200
Study Start Date:	March 2008

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.

Exclusion Criteria:

No other patients except those listed above will be recruited.
Additionally, patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00767936

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Mei-Sze Chua 650-724-3525 mchua@stanford.edu
Contact: Cancer Clinical Trials Office (650) 498-7061
Principal Investigator: Samuel So
Sub-Investigator: Mei-Sze Chua

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Samuel So

Stanford University

More Information

Study ID Numbers:	SU-05222008-1183, 98795, HEP0013
Study First Received:	October 3, 2008
Last Updated:	October 6, 2008
ClinicalTrials.gov Identifier:	NCT00767936
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Liver Diseases
Digestive System Neoplasms
Carcinoma, Hepatocellular
Liver neoplasms
Hepatitis, Viral, Human
Carcinoma
Liver Neoplasms
Hepatitis
Virus Diseases

Digestive System Diseases
Hepatitis B
Gastrointestinal Neoplasms
DNA Virus Infections
Hepatitis C
Adenocarcinoma
Hepatocellular carcinoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Neoplasms
RNA Virus Infections
Neoplasms by Site

Neoplasms by Histologic Type
Flaviviridae Infections
Hepadnaviridae Infections

ClinicalTrials.gov processed this record on January 16, 2009